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The systemic exposure to tacrolimus after ﬁrst and repeated application of 0.1% tacrolimus ointment was inves-
tigated in 32 adults with moderate to severe atopic dermatitis. Patients were allocated to treatment groups ac-
cording to the size of the affected area to be treated: Group 1p3000 cm2 (N¼ 11); Group 243000 cm2p6000 cm2
(N¼ 12); Group 346000 cm2p10,000 cm2 (N¼ 9). Ointment was applied twice daily for 13 d and once daily on Day
14; the size of application area remained the same irrespective of healing. Blood samples were collected on Days 1
(ﬁrst application), 4, and 14 (last application) and analyzed by a validated HPLC-MS/MS method. Systemic exposure
to tacrolimus was generally low with 96% of blood samples assayed containing concentrations below 1 ng per mL
and 23% of samples below the lower limit of quantiﬁcation (0.025 ng per mL). Peak concentrations after ﬁrst
ointment application were p2.8 ng per mL, and the mean area under the concentration–time curve between 0 and
12 h using the trapezoidal rule (AUC0–12) values were 1.1, 1.6, and 4.8 ng h per mL for Groups 1, 2, and 3, re-
spectively. The corresponding mean values on Day 14 were similar indicating negligible systemic accumulation of
tacrolimus after repeated ointment applications. Both the rate and extent of topical absorption decreased as the
skin lesions healed.
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Atopic dermatitis is a common, chronic, inflammatory skin
disease characterized by intense itching and eczematous
lesions. Emollients afford some symptomatic relief by help-
ing prevent water loss and painful cracking of the skin, but
disease exacerbations often require treatment with topical
corticosteroids, the prolonged application of which can be
associated with dermal atrophy and other side effects
(Furue et al, 2003). Therefore there is a need for an alter-
native treatment that is efficacious, and free of the long-
term side effects associated with corticosteroids.
Tacrolimus is a calcineurin inhibitor and reduces inflam-
mation by suppressing T-lymphocyte responses (Chher and
Plosker, 2001). Clinical trials in adults (Ruzicka et al, 1997;
Hanifin et al, 2001; Soter et al, 2001) and children (Bog-
uniewicz et al, 1998; Kang et al, 2001; Paller et al, 2001)
have shown that tacrolimus ointment is extremely effective
in treating and controlling moderate to severe atopic der-
matitis. Systemic exposure to tacrolimus following ointment
application is low and absorption decreases as the skin le-
sions heal (Paller et al, 2001; Soter et al, 2001).
To gain additional knowledge of the systemic exposure
to tacrolimus following first and repeated ointment applica-
tion, 0.1% tacrolimus ointment was applied for 14 d to dif-
ferent sizes of treatment area in adults with moderate to
severe atopic dermatitis. The main study objective was to
investigate the pharmacokinetics of tacrolimus in relation to
increasing treatment surface area. Clinical efficacy was as-
sessed by measuring the improvement in the body surface
areas treated.
Results
Demographic and baseline characteristics The treat-
ment groups were comparable with respect to age, weight,
height, and estimated total body surface area. In Group 3,
there were more patients with a grading of severe atopic
dermatitis at baseline compared with the other two treat-
ment groups.
Patient disposition Two patients withdrew from the study
prior to active treatment and three patients did not provide
complete pharmacokinetic profiles and were excluded from
the study. Therefore complete sets of data for pharmaco-
kinetic analyses were obtained for 32 patients (Group 1,
N¼ 11; Group 2, N¼ 12; Group 3, N¼ 9).
Treatment area and tacrolimus dosage The mean size
of treatment areas were 2410  454 cm2 (Group 1),
4104  872 cm2 (Group 2) and 8553  1308 cm2 (Group
3). On Day 1, the patients in Groups 1 and 2 both received a
mean tacrolimus dose of 0.05 mg per kg while in Group 3,
the mean tacrolimus dose was 0.11 mg per kg. As the
Abbreviations: AUC0–12, area under the concentration–time curve
between 0 and 12 h using the trapezoidal rule
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condition of the skin improved, less ointment was required
to cover the treatment area and the tacrolimus dose de-
creased; on Day 14, the respective mean doses were 0.03,
0.04, and 0.07 mg per kg.
Pharmacokinetic parameters Pharmacokinetic parame-
ters were determined for all three profiles and are shown
in Table I.
In general, the systemic exposure to tacrolimus was low
and highly variable in all three treatment groups. Overall
96% of all the blood samples assayed contained tacrolimus
concentrations below 1 ng per mL and 23% of samples
were below the lower limit of quantification of the assay
(0.025 ng per mL). The mean blood concentration-time pro-
files (Fig 1a–c) show that the exposure to tacrolimus de-
creased between Day 4 and 14 in all three treatment groups
as the condition of the skin improved.
Systemic exposure to tacrolimus tended to increase as
the size of the treated body surface area increased. The
higher tacrolimus blood levels observed, however, were still
very low, especially when compared to the tacrolimus blood
levels present in adult transplant recipients administered
tacrolimus systemically (Fig 2). The mean area under the
concentration–time curve between 0 and 12 h using the
trapezoidal rule (AUC0—12) values for Groups 1, 2, and 3
following the first application of ointment were 1.1, 1.6, and
4.8 ng h per mL, respectively. The mean AUC0–12 values
measured on Day 14 were comparable to those on Day 1
(Table I), indicating a decrease in percutaneous absorption
and no accumulation of tacrolimus.
A similar trend was observed with the mean maximum
concentration values (Cmax). There were no clear trends
discernible for the times to maximum concentration (tmax)
among the three treatment groups.
The mean disposition half-life (t1/2) estimated from Day 1
blood-concentration data was similar in the three treatment
groups (8.6, 9.4, and 8.5 h for Groups 1, 2, and 3, respec-
tively). There was high individual variation in this parameter
with values ranging from 2.7 to 18.0 h. Blood samples were
collected for up to 7 d after the last application of ointment
and an apparent slower elimination half-life was observed
(mean: 76  22 h; range: 51–136 h).
Clinical improvement Most patients experienced consid-
erable clinical improvement during the 14-d-treatment pe-
riod (Table II). By Day 14, there was a large reduction in the
mean size of the affected body surface area in each of the
treatment groups. The patients in Group 1 experienced the
largest reduction (66.3%) followed by Group 3 (42.0%) and
Group 2 (26.3%).
The improvement in clinical condition achieved with the
0.1% tacrolimus ointment is also reflected in the physician’s
global evaluation of clinical response. Seven patients
(21.9%) obtained a rating of ‘‘moderate’’ improvement (de-
fined as X50% improvement); 14 patients (43.8%) received
Figure1
Tacrolimus blood concentration–time profiles. (a) Mean tacrolimus
blood concentration–time profile (Day 1). (b) Mean tacrolimus blood
concentration–time profile (Day 4). (c) Mean tacrolimus blood concen-
tration–time profile (Day 14).
Table I. Pharmacokinetic parameters of tacrolimus in adults
after ﬁrst and repeated application of 0.1% tacrolimus ointment
(N¼ 32)
Cmax (ng per mL)
Mean  SD
tmax (h)
Median
AUC0–12 (ng h per mL)
Mean  SD
Day 1
Group 1 0.14  0.16 4 1.1  1.4
Group 2 0.25  0.42 4 1.6  2.8
Group 3 0.66  0.85 4 4.8  6.3
Day 4
Group 1 0.21  0.24 2 2.1  2.3
Group 2 1.10  2.78 7 3.9  5.0
Group 3 0.96  0.80 4 10.2  9.2
Day 14
Group 1 0.60  1.62 2 1.7  2.3
Group 2 0.19  0.22 3 1.5  1.5
Group 3 0.65  0.38 4 5.4  2.8
AUC0–12, area under the concentration–time curve between 0 and 12 h
using the trapezoidal rule.
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a rating of ‘‘marked’’ improvement (X75%–89%) while seven
patients (21.9%) experienced ‘‘excellent’’ improvement
(90%–99%) and one patient (3.1%) achieved clearance.
Only one patient had no appreciable improvement during
the study.
Skin irritation (skin burning, itching) was the most fre-
quently reported adverse event. Altogether 10 patients
(31.2%) experienced transient skin irritation (Group 1: two
patients; Group 2: five patients; Group 3: four patients)
which, in most cases, was mild to moderate in severity and
normally resolved within 10–15 min. None of the patients
discontinued treatment because of skin irritation, and the
sensation of skin burning resolved completely after the first
four days of treatment. There were no serious adverse
events or adverse events leading to treatment discontinu-
ation. There were no clinically relevant changes in labora-
tory assessments.
Discussion
The data presented here are consistent with those pub-
lished previously (Paller et al, 2001; Soter et al, 2001) and
show that although tacrolimus applied topically is ab-
sorbed, the overall systemic exposure to the drug as meas-
ured by AUC0–12 is low and highly variable. There was a
tendency for systemic exposure to increase proportionally
as the size of treatment area increased, but exposure was
still substantially lower than for transplant patients. Al-
though a direct measure of systemic bioavailability following
the topical application of the ointment was not made in this
study, the highest mean value of AUC(0–12), 10.2 ng h per mL
measured during the study was only 3% of the correspond-
ing value for kidney transplant patients (346 ng h per mL)
administered an oral tacrolimus dose of 0.2 mg per kg per
12 h (Undre et al, 1998). In addition to the observed low
systemic exposure, the pre-dose and minimum concentra-
tion measurements indicate that, despite repeated applica-
tions of 0.1% tacrolimus ointment to the same treatment
area, there is no systemic accumulation of tacrolimus.
The patients with the larger treatment areas had more
severe atopic dermatitis and a higher number of open le-
sions, which probably led to an initially higher absorption of
tacrolimus. The blood concentration–time profiles show that
as the skin lesions healed, the systemic exposure to ta-
crolimus decreased. A decrease in the percutaneous pen-
etration of tacrolimus over the dosing time interval also
becomes evident when the other pharmacokinetic data are
considered. The mean disposition t1/2 on Day 1 of 8–9 h is
shorter than the elimination half-life of 40 h measured in
healthy subjects (Mo¨ller et al, 1999) and therefore reflects
absorption and elimination processes occurring concur-
rently. Furthermore, the mean t1/2,z after the last application
of ointment was longer than the systemic half-life of ta-
crolimus in healthy subjects; this apparent longer half-life is
probably attributable to the rate of absorption being slower
than the rate of elimination. This observation, combined
with the fact that the AUC(0–12) values on Day 14 and 1 were
similar, indicates that both the extent and rate of topical
absorption of tacrolimus decreases as the condition of the
skin improves. These data suggest therefore that in this
patient population, due to the decrease in percutaneous
absorption, 0.1% tacrolimus ointment should be applied
twice daily.
Although the study was of short duration as it was de-
signed primarily to determine the pharmacokinetics of 0.1%
tacrolimus ointment, we observed considerable improve-
ment in the clinical condition of most patients. There were
no clinical safety concerns associated with the ointment.1
In conclusion, these pharmacokinetic data confirm that
patients applying 0.1% tacrolimus ointment have low sys-
temic exposure to tacrolimus and there was no evidence of
systemic accumulation. Furthermore, 0.1% tacrolimus oint-
ment is efficacious and well-tolerated by adults with mod-
erate to severe atopic dermatitis.
Figure 2
Comparative absorption of tacrolimus. Area under the curve of ta-
crolimus in adult atopic dermatitis patients treated with 0.1% ta-
crolimus ointment compared with adult kidney transplant patients
administered tacrolimus systemically.
Table II. Measurement of clinical efﬁcacy of 0.1% tacrolimus
ointment
Mean affected
BSA (cm2)
Percentage
decreaseDay 1 Day 14
Group 1p3000 cm2 2344 790 66.3
Group 243000 cm2p6000 cm2 4104 3025 26.3
Group 346000 cm2p10,000 cm2 8609 4995 42.0
Physican’s assessment of global response—number of patients (%)
Cleared 1 (3.1%)
Excellent 7 (21.9%)
Marked 14 (43.8%)
Moderate 7 (21.9%)
Slight improvement 2 (6.3%)
No appreciable improvement 1 (3.1%)
BSA, bovine serum albumin.
1The FDA is currently considering whether to add a black box
warning about the theoretical risk of malignancies in atopic der-
matitis patients applying topical treatments containing calcineurin
inhibitors.
70 RUBINS ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Materials and Methods
Study design This was a single-center, open, phase II pharmaco-
kinetics study. The study was conducted in accordance with the
ethical principles described in the Declaration of Helsinki, and the
Ethics Committee of the study center (Zalu kliniskas izpetes Etikas
komiteja, Riga, Latvia) reviewed the protocol and granted approval
before the start of the study. A screening visit was carried out
seven days before the baseline visit (Day 1, ointment application).
Patients Following written informed consent from the patient, 37
male and female patients aged 18 y or older with a diagnosis of
atopic dermatitis based on the criteria of Hanifin and Rajka (1980)
were enrolled into the study. The patients were required to have a
grading of moderate to severe atopic dermatitis (i.e., score at least
4.5) as defined by the scoring system of Rajka and Langeland
(1989) which rates extent, course and intensity of the disease
separately before summing up the three scores to determine over-
all severity. At the Day 1 visit, the area to be treated was defined by
the physician and the patients were allocated to one of three
groups according to the size of treatment area: Group 1p3000
cm2; Group 243000 cm2 to p6000 cm2; Group 346000 cm2 to
p10,000 cm2.
Treatment The patients received two applications of 0.1% ta-
crolimus ointment on each day, except for Day 14 when the oint-
ment was applied only once so that a full pharmacokinetic profile
to 168 h could be obtained. The size of the application area re-
mained the same irrespective of healing. On Days 1 and 4, the first
of the two ointment treatments was applied by the investigator as
was the single application on Day 14. All other ointment applica-
tions were performed by the patient at home.
Assessments Pharmacokinetic profiling, using the tacrolimus as-
say as described by Hill et al (1997), took place on Days 1, 4, and
14. Blood concentration–time profiles were attained by collecting
serial blood samples (2.5 mL into EDTA monovettes). The blood
samples were immediately frozen and stored at 201C before be-
ing shipped to the contract research laboratory that performed the
analyses. Profile 1 comprised a pre-dose blood sample (0 h) fol-
lowed by samples taken 2, 4, 6, 8, 10, and 12 h after first appli-
cation of 0.1% tacrolimus ointment while Profile 2 consisted of
samples taken pre-dose, 2, 4, 8, and 12 h following ointment ap-
plication on Day 4. Profile 3 comprised a pre-dose sample and
samples taken 2, 4, 8, 12, 24, 48, 72, 96, 120, 144, and 168 h after
the last application of ointment. Internal standard (32-0-acetyl
derivative of tacrolimus (Fujisawa, Osaka, Japan)) and protein
precipitation reagent (aqueous zinc sulfate solution (Sigma,
Dorset, UK): methanol (Romil, Cambridge, UK): acetonitrile (Romil)
50:30:20) were added to the samples. Solid phase extraction (us-
ing 18C cartridges (Anachem, Luton, UK)) of analytes was per-
formed before injection onto the liquid chromatography mass
spectrometer (Sciex API III Plus, Perkin-Elmer, Beaconsfield, UK).
The lower limit of quantification for this method was 0.025 ng per
mL with a precision, based on the co-efficient of variation, of less
than 12.3%. All of the procedures were performed according to
OECD-GLP guidelines.
The maximum blood concentration (Cmax), time to attain Cmax
(tmax), minimum concentration (Cmin) and pre-dose blood concen-
tration (C0) were read directly from the individual blood concen-
tration-time profiles. Non-compartmental analysis was used to
determine the AUC0–12, the disposition half-life (t1/2) and terminal
half-life (t1/2,z). For calculation of AUC0–12, concentrations less than
the lower limit of quantification were set to zero.
Safety assessments were based on laboratory blood tests,
clinical adverse events and the changes from baseline of the
physical examinations. Clinical efficacy was evaluated according
to the ratings of the physician’s global evaluation of clinical re-
sponse made on Days 1 and 14, and the decrease in total affected
body surface area. For the physician’s global evaluation of clinical
response, the investigator rated the change from baseline in the
patient’s overall clinical status. The investigator reported ‘‘cleared’’
to indicate improvement of 100%, ‘‘excellent’’ for improvement of
90%–99%, ‘‘marked’’ for 75%–89%, ‘‘moderate’’ for 50%–74%,
‘‘slight’’ for 30%–49%, ‘‘no appreciable improvement’’ for 0%–
29%, and ‘‘worse’’ for worsening of the condition. Total affected
body surface area was calculated by multiplying the percentage
affected area of each body region (head/neck, upper limbs, trunk
and lower limbs) by the following factors (head/neck 0.1; upper
limbs 0.2; trunk 0.3, and lower limbs 0.4) to give the sum of the
total affected area.
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